Global Markets Direct: Market Research Reports

Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.

A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.

The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.

With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.

Under the supervision of skillful managers and experts, business analysts produce reports that include:

Product portfolio
Potentially strong market reviews
Competitive analytics
Prospect partners
Mergers and acquisitions project data
Latest trends across a particular industry area
Research and development strategies
The analysis of new customers
A set of remedial measures for projects

They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.

Publications found: 5,853

Sort by:

Born Small For Gestational Age (SGA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Born Small For Gestational Age (SGA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Born Small For Gestational Age (SGA) Drugs in Development by Stages, Target...

May 2022 35 pages

Brachyury Protein (Protein T or T) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Brachyury Protein (Protein T or T) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Brachyury Protein (Protein T or T) Drugs in Developmen...

May 2022 36 pages

Brain Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Brain Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Brain Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provid...

May 2022 161 pages

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Brain Derived Neurotrophic Factor (Abrineurin or BDNF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Brain Derived Neurotrophic Factor...

May 2022 43 pages

Brain (Head) Trauma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Brain (Head) Trauma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Brain (Head) Trauma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key...

May 2022 35 pages

Brain Hemorrhage Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Brain Hemorrhage Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Brain Hemorrhage Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Player...

May 2022 50 pages

Brain Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Brain Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Brain Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides...

May 2022 119 pages

Bronchiolitis Obliterans Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Bronchiolitis Obliterans Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Bronchiolitis Obliterans Drugs in Development by Stages, Target, MoA, RoA, Molecule Typ...

May 2022 39 pages

Burkholderia Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Burkholderia Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Burkholderia Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 45 pages

Burkitt Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Burkitt Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Burkitt Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Player...

May 2022 94 pages

C-C Chemokine Receptor Type 2 (Monocyte Chemoattractant Protein 1 Receptor or CD192 or CCR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

C-C Chemokine Receptor Type 2 (Monocyte Chemoattractant Protein 1 Receptor or CD192 or CCR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMM...

May 2022 40 pages

C-C Chemokine Receptor Type 9 (G Protein Coupled Receptor 28 or GPR 9-6 or CDw199 or CCR9) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

C-C Chemokine Receptor Type 9 (G Protein Coupled Receptor 28 or GPR 9-6 or CDw199 or CCR9) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMAR...

May 2022 35 pages

Cachexia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cachexia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cachexia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an ov...

May 2022 51 pages

Calcineurin (Protein Serine-Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Calcineurin (Protein Serine-Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMM...

May 2022 75 pages

Calcium Activated Neutral Protease (Calpain or CANP or CAPN or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Calcium Activated Neutral Protease (Calpain or CANP or CAPN or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Calcium Activa...

May 2022 52 pages

Calcium Activated Potassium Channel Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Calcium Activated Potassium Channel Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Calcium Activated Potassium Channel Drugs in Developm...

May 2022 51 pages

Calcium-Calmodulin Dependent Protein Kinase Type II (CAMK2 or EC 2.7.11.17) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Calcium-Calmodulin Dependent Protein Kinase Type II (CAMK2 or EC 2.7.11.17) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Calcium/Calmo...

May 2022 39 pages

Calcium Release Activated Calcium Channel Protein 1 (Protein Orai 1 or Transmembrane Protein 142A or ORAI1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Calcium Release Activated Calcium Channel Protein 1 (Protein Orai 1 or Transmembrane Protein 142A or ORAI1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and K...

May 2022 41 pages

Calcium Sensing Receptor Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Calcium Sensing Receptor Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Calcium Sensing Receptor Drugs in Development by Therapy Areas a...

May 2022 40 pages

Calreticulin (Calregulin or Endoplasmic Reticulum Resident Protein 60 or CRP55 or HACBP or grp60 or CALR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Calreticulin (Calregulin or Endoplasmic Reticulum Resident Protein 60 or CRP55 or HACBP or grp60 or CALR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...

May 2022 39 pages

cAMP Specific 3,5 Cyclic Phosphodiesterase 4B (DPDE4 or PDE32 or PDE4B or EC 3.1.4.53) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

cAMP Specific 3,5 Cyclic Phosphodiesterase 4B (DPDE4 or PDE32 or PDE4B or EC 3.1.4.53) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY cA...

May 2022 36 pages

Cancer-Testis Antigen 1 (Autoimmunogenic Cancer-Testis Antigen NY ESO 1 or Cancer-Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cancer-Testis Antigen 1 (Autoimmunogenic Cancer-Testis Antigen NY ESO 1 or Cancer-Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) Drugs in Development by Therapy Areas and Indicat...

May 2022 48 pages

Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cannabinoid Receptor 1 (CB1 or CANN6 or CNR...

May 2022 298 pages

Cannabinoid Receptor 2 (CB2 or CX5 or CNR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Cannabinoid Receptor 2 (CB2 or CX5 or CNR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cannabinoid Receptor 2 (CB2 or CX5 or CNR2) D...

May 2022 292 pages

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54-58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54-58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4.2.1.1) Drugs in Development by Therapy Areas and...

May 2022 40 pages

Carbonic Anhydrase (Carbonate Dehydratase or Carbonic Acid Anhydrase or Carboxyanhydrase or CA or EC 4.2.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Carbonic Anhydrase (Carbonate Dehydratase or Carbonic Acid Anhydrase or Carboxyanhydrase or CA or EC 4.2.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and...

May 2022 54 pages

Carcinoembryonic Antigen (CEA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Carcinoembryonic Antigen (CEA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Carcinoembryonic Antigen (CEA) Drugs in Development by The...

May 2022 51 pages

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Drugs in Development by Therapy Areas and Indications, Stages, M...

May 2022 38 pages

Carcinoid Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Carcinoid Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Carcinoid Tumor Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players...

May 2022 40 pages

Carcinomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Carcinomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Carcinomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides a...

May 2022 266 pages

Cardiometabolic Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cardiometabolic Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cardiometabolic Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 47 pages

Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players pr...

May 2022 122 pages

Cardiovascular Inflammation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cardiovascular Inflammation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cardiovascular Inflammation Drugs in Development by Stages, Target, MoA, RoA, Molecu...

May 2022 76 pages

Carotid Artery Stenosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Carotid Artery Stenosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Carotid Artery Stenosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 35 pages

Cartilage Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cartilage Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cartilage Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type an...

May 2022 43 pages

Casein Kinase 2 (CSNK2 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Casein Kinase 2 (CSNK2 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Casein Kinase 2 (CSNK2 or EC 2.7.11.1) Drugs in De...

May 2022 40 pages

Casein Kinase I Isoform Alpha (CKI Alpha or CK1 or CSNK1A1 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Casein Kinase I Isoform Alpha (CKI Alpha or CK1 or CSNK1A1 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Casein Kinase...

May 2022 37 pages

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type a...

May 2022 37 pages

Caspase 1 (Interleukin 1 Beta Convertase or Interleukin 1 Beta Converting Enzyme or p45 or CASP1 or EC 3.4.22.36) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Caspase 1 (Interleukin 1 Beta Convertase or Interleukin 1 Beta Converting Enzyme or p45 or CASP1 or EC 3.4.22.36) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type...

May 2022 39 pages

Caspase (CASP or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Caspase (CASP or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Caspase (CASP or EC 3.4.22.) Drugs in Development by Therapy...

May 2022 66 pages

CD276 Antigen (B7 Homolog 3 or 4Ig B7 H3 or Costimulatory Molecule or B7H3 or CD276) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

CD276 Antigen (B7 Homolog 3 or 4Ig B7 H3 or Costimulatory Molecule or B7H3 or CD276) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY CD27...

May 2022 35 pages

CD44 Antigen (CDw44 or Epican or Extracellular Matrix Receptor III or GP90 Lymphocyte Homing-Adhesion Receptor or HUTCH I or Heparan Sulfate Proteoglycan or Hermes Antigen or Hyaluronate Receptor or Phagocytic Glycoprotein 1 or CD44) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

CD44 Antigen (CDw44 or Epican or Extracellular Matrix Receptor III or GP90 Lymphocyte Homing-Adhesion Receptor or HUTCH I or Heparan Sulfate Proteoglycan or Hermes Antigen or Hyaluronate Receptor or P...

May 2022 37 pages

Cells Expressing ADP Ribosyl Cyclase-Cyclic ADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2 Phospho ADP Ribosyl Cyclase-2 Phospho Cyclic ADP Ribose Transferase or ADP Ribosyl Cyclase 1 or CD38 or EC 3.2.2.6 or EC 2.4.99.20) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing ADP Ribosyl Cyclase-Cyclic ADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2 Phospho ADP Ribosyl Cyclase-2 Phospho Cyclic ADP Ribose Transferase or ADP Ribosyl Cyclase...

May 2022 86 pages

Cells Expressing ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...

May 2022 35 pages

Cells Expressing Alpha Fetoprotein (Alpha 1 Fetoprotein or Alpha Fetoglobulin or AFP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Alpha Fetoprotein (Alpha 1 Fetoprotein or Alpha Fetoglobulin or AFP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cel...

May 2022 40 pages

Cells Expressing Cancer-Testis Antigen 1 (Autoimmunogenic Cancer-Testis Antigen NY ESO 1 or Cancer-Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Cancer-Testis Antigen 1 (Autoimmunogenic Cancer-Testis Antigen NY ESO 1 or Cancer-Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) Drugs in Development by Therapy...

May 2022 74 pages

Cells Expressing CD276 Antigen (B7 Homolog 3 or 4Ig B7 H3 or Costimulatory Molecule or B7H3 or CD276) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing CD276 Antigen (B7 Homolog 3 or 4Ig B7 H3 or Costimulatory Molecule or B7H3 or CD276) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Pla...

May 2022 73 pages

Cells Expressing CD3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing CD3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing CD3 Drugs in Development by Therapy Areas and Indic...

May 2022 39 pages

Cells Expressing CD44 Antigen (CDw44 or Epican or Extracellular Matrix Receptor III or GP90 Lymphocyte Homing-Adhesion Receptor or HUTCH I or Heparan Sulfate Proteoglycan or Hermes Antigen or Hyaluronate Receptor or Phagocytic Glycoprotein 1 or CD44) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing CD44 Antigen (CDw44 or Epican or Extracellular Matrix Receptor III or GP90 Lymphocyte Homing-Adhesion Receptor or HUTCH I or Heparan Sulfate Proteoglycan or Hermes Antigen or Hyaluron...

May 2022 39 pages

Cells Expressing CD70 Antigen (CD27 Ligand or Tumor Necrosis Factor Ligand Superfamily Member 7 or CD70) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing CD70 Antigen (CD27 Ligand or Tumor Necrosis Factor Ligand Superfamily Member 7 or CD70) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...

May 2022 42 pages